Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allosteric Regulation01:08

Allosteric Regulation

64.9K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
64.9K
Allosteric Regulation01:08

Allosteric Regulation

16.5K
16.5K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.5K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

7.0K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
7.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

6.0K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration.

Drugs and drug candidates·2026
Same author

Nascent Pre-Platelets and B4GALT1 Glycosylation Contribute to 5-FU-induced Bone Marrow Recovery.

Blood advances·2026
Same author

Chemical Synthesis and Biochemical Evaluation of Decasulfated Galloylglucopyranose Heparin Mimetic.

Cardiovascular & hematological agents in medicinal chemistry·2026
Same author

Advancing Environmental Justice through Chemical Education: Perspective from New Orleans' Water and Air Quality Challenges.

Journal of chemical education·2026
Same author

The excessive, opportunistic price increase of generic oncology drug floxuridine.

Journal of cancer policy·2026
Same author

Developing Safer Anticoagulant Candidates: Structure-Activity Relationship Studies of 5-Amino-Triazole-Based FXIIa Inhibitors.

Medicinal chemistry (Shariqah (United Arab Emirates))·2026

Related Experiment Video

Updated: Apr 18, 2026

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
06:45

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

3.0K

Plasmin regulation through allosteric, sulfated, small molecules.

Rami A Al-Horani1, Rajesh Karuturi2, Domonique T White3

  • 1Department of Medicinal Chemistry and Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, VA 23219, USA. alhoranir@vcu.edu.

Molecules (Basel, Switzerland)
|January 9, 2015
PubMed
Summary

Researchers discovered the first small, synthetic allosteric inhibitors for plasmin, a key enzyme in clot lysis. These compounds offer a new avenue for developing targeted therapies by selectively inhibiting plasmin activity.

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

143

Related Experiment Videos

Last Updated: Apr 18, 2026

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
06:45

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

3.0K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

143

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Plasmin is a crucial serine protease involved in blood clot breakdown (lysis) and tissue remodeling.
  • While heparin modulates plasmin activity, no small molecule allosteric inhibitors have been identified.
  • Developing small molecule inhibitors is vital for targeted therapeutic interventions.

Purpose of the Study:

  • To screen for and identify small molecule allosteric inhibitors of plasmin.
  • To characterize the inhibitory mechanism and selectivity of identified compounds.
  • To establish a foundation for the rational design of novel plasmin inhibitors.

Main Methods:

  • Screening of a library containing 55 sulfated glycosaminoglycan mimetics across nine scaffolds.
  • In vitro enzymatic assays to determine inhibitory potency (IC50) and efficacy.
  • Michaelis-Menten kinetic analysis to elucidate the inhibition mechanism.
  • Selectivity profiling against related serine proteases like thrombin and factor Xa.

Main Results:

  • Identified several promising small molecule inhibitors of plasmin.
  • A pentasulfated flavonoid-quinazolinone dimer (compound 32) demonstrated potent inhibition (IC50 = 45 μM, 100% efficacy).
  • Inhibitors act via an allosteric mechanism, showing selectivity for plasmin over thrombin and factor Xa.
  • Varied efficacies (40%-100%) among inhibitors highlight the nuances of allosteric modulation.

Conclusions:

  • This study reports the first small, synthetic allosteric inhibitors of plasmin.
  • These compounds represent a significant advancement in the development of targeted plasmin-modulating agents.
  • The findings provide a basis for future drug design and optimization of plasmin inhibitors.